ArticleNature communications2022
Robust and durable serological response following pediatric SARS-CoV-2 infection.
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 87 citations in OpenAlex.
- Variant-Specific Kinetics of SARS-CoV-2 Anti-Nucleocapsid Antibodies and Household Transmission in Families During Anchestral, Alpha, Delta and Omicron Periods.Life (Basel, Switzerland) · 2026Article
- High serological barriers may contribute to restricted Influenza-A-virus transmission between pigs and humans.One health (Amsterdam, Netherlands) · 2025Article
- Characterising protective immune responses to SARS-CoV-2 in urban and rural Malawi between February 2021 and April 2022.Scientific reports · 2025Article
- SARS-CoV-2 antibody responses in children exhibit higher FcR engagement and avidity than in adults.Nature communications · 2025Article
- Antibodies against SARS-CoV-2 in children and adolescents: a one-year longitudinal study.BMJ paediatrics open · 2025Article
- Longitudinal analysis of humoral and cellular immunity in SARS-CoV-2 exposed families.Scientific reports · 2025Article
- Age-dependent ACE2/TMPRSS2 expression and SARS-CoV-2 household transmission in Gran Canaria.PloS one · 2025Observational
- The quantity and quality of B-cell immunity against SARS-CoV-2 in children with cancer and hematological diseases.Frontiers in immunology · 2025Article
- SARS-CoV-2 Infections in a Triad of Primary School Learners (Grades 1-7), Their Parents, and Teachers in KwaZulu-Natal, South Africa: Protocol for a Cross-Sectional and Nested Case-Cohort Study.JMIR research protocols · 2024Article
- Elevated Soluble ACE2 Activity in Children and Adults After SARS-CoV-2 Exposure Irrespective of Laboratory-Confirmed Infection.Journal of medical virology · 2024Article
- Booster Vaccination with BNT162b2 Improves Cellular and Humoral Immune Response in the Pediatric Population Immunized with CoronaVac.Vaccines · 2024Article
- Long-term surveillance of SARS-CoV-2 in the school community from Campo Grande, Brazil.BMC public health · 2024Article
- Long-term immune response to SARS-CoV-2 infection and vaccination in children and adolescents.Pediatric research · 2024Article
- The Effect of Age and Comorbidities: Children vs. Adults in Their Response to SARS-CoV-2 Infection.Viruses · 2024Article
- Article
- Durability of immune responses to SARS-CoV-2 infection and vaccination.Seminars in immunology · 2024Review
- Severe pediatric COVID-19: a review from the clinical and immunopathophysiological perspectives.World journal of pediatrics : WJP · 2024Review
- Article
- Primary SARS-CoV-2 infection in children and adults results in similar Fc-mediated antibody effector function patterns.Clinical & translational immunology · 2024Article
- Variant-specific antibody profiling for tracking SARS-CoV-2 variant infections in children and adolescents.Frontiers in immunology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
50 authors at 8 institutions in 2 countries.
Funding
Abstract
The quality and persistence of children's humoral immune response following SARS-CoV-2 infection remains largely unknown but will be crucial to guide pediatric SARS-CoV-2 vaccination programs. Here, we examine 548 children and 717 adults within 328 households with at least one member with a previous laboratory-confirmed SARS-CoV-2 infection. We assess serological response at 3-4 months and 11-12 months after infection using a bead-based multiplex immunoassay for 23 human coronavirus antigens including SARS-CoV-2 and its Variants of Concern (VOC) and endemic human coronaviruses (HCoVs), and additionally by three commercial SARS-CoV-2 antibody assays. Neutralization against wild type SARS-CoV-2 and the Delta VOC are analysed in a pseudotyped virus assay. Children, compared to adults, are five times more likely to be asymptomatic, and have higher specific antibody levels which persist longer (96.2% versus 82.9% still seropositive 11-12 months post infection). Of note, symptomatic and asymptomatic infections induce similar humoral responses in all age groups. SARS-CoV-2 infection occurs independent of HCoV serostatus. Neutralization responses of children and adults are similar, although neutralization is reduced for both against the Delta VOC. Overall, the long-term humoral immune response to SARS-CoV-2 infection in children is of longer duration than in adults even after asymptomatic infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.